These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8581397)

  • 1. Serum tumour markers and management of non-small cell lung cancer.
    Splinter TA
    Lung Cancer; 1995 Oct; 13(2):177-9. PubMed ID: 8581397
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
    Nicolazzo C; Raimondi C; Loreni F; Gazzaniga P; Gradilone A
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prescription of serum tumor markers in a general hospital].
    Watine J; Charet JC; Augé MC
    Presse Med; 1998 May; 27(18):862, 864. PubMed ID: 9767874
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
    Alama A; Coco S; Vanni I; Grossi F
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.
    Isbell JM; Jones DR; Li BT
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2628-2631. PubMed ID: 29615336
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic and diagnostic usefulness of serum markers in lung cancer.
    Stahel RA; Martz G
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):893-4. PubMed ID: 2822425
    [No Abstract]   [Full Text] [Related]  

  • 7. Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer patients.
    De Vita F; Infusino S; Auriemma A; Orditura M; Catalano G
    Oncol Rep; 1998; 5(2):393-6. PubMed ID: 9468565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurone-specific enolase and other neuroendocrine markers in lung cancer.
    Ledermann JA
    Eur J Cancer; 1994; 30A(5):574-6. PubMed ID: 8080666
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in patients with non-small cell lung cancer after surgery.
    Ju X; Zheng L; Niu Y; Guan H; Luo H
    Asian J Surg; 2020 Sep; 43(9):940-941. PubMed ID: 32522378
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
    Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K
    Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
    Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
    BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors confounding evaluation of treatment effect in lung cancer.
    Osterlind K
    Lung Cancer; 1994 Mar; 10 Suppl 1():S97-103. PubMed ID: 8087532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma.
    Gao W; Liu L; Lu X; Shu Y
    Clin Lung Cancer; 2011 Jan; 12(1):14-7. PubMed ID: 21273174
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy.
    Tokito T; Azuma K; Yamada K; Naito Y; Matsuo N; Ishii H; Natori H; Kinoshita T; Hoshino T
    In Vivo; 2019; 33(3):889-895. PubMed ID: 31028213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved detection of stage I non-small cell lung cancer with a serum-based assay.
    Burt BM
    J Thorac Cardiovasc Surg; 2015 Mar; 149(3):735-6. PubMed ID: 25598528
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumour marker evaluation in patients with lung cancer.
    Seregni E; Botti C; Bogni A; Bombardieri E
    Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer.
    Demirkazik A; Akbulut H; Ulger AF; Arican A; Ozer I; Acikgoz N; Icli F
    Ann Saudi Med; 2004; 24(6):473-5. PubMed ID: 15646168
    [No Abstract]   [Full Text] [Related]  

  • 19. Elastase levels in small and non-small cell lung carcinoma.
    Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomarkers in lung cancer.
    Bearz A; Berretta M; Cappellani A; Lleshi A; Berto E; Fratino L; Tirelli U
    Front Biosci (Elite Ed); 2010 Jun; 2(3):1099-104. PubMed ID: 20515780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.